Compugen Ltd. (NASDAQ: CGEN)
today announced that Ari Krashin, Chief Financial Officer of Compugen,
will present a corporate overview and update at the JMP Securities Life
Sciences Conference in New York on Wednesday, June 24 at 11:00 a.m. ET.
About Compugen
Compugen is a leading predictive drug discovery company focused on
monoclonal antibodies and therapeutic proteins to address important
unmet needs in the fields of oncology and immunology. The Company
utilizes a broad and continuously growing integrated infrastructure of
proprietary scientific understandings and predictive platforms,
algorithms, machine learning systems and other computational biology
capabilities for the in silico (by computer) prediction and
selection of novel drug target candidates, which are then advanced in
its Pipeline Program. The discovery and development of monoclonal
antibody therapeutic candidates against selected Compugen-discovered
novel target candidates is performed by Compugen’s wholly-owned US
subsidiary located in South San Francisco. The Company's business model
includes collaborations covering the further development and
commercialization of product candidates at various stages from its
Pipeline Program and various forms of research and discovery agreements,
in both cases providing Compugen with potential milestone payments and
royalties on product sales or other forms of revenue sharing. For
additional information, please visit Compugen's corporate website at www.cgen.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150615005583/en/
Copyright Business Wire 2015